Discovery of a potent FKBP38 agonist that ameliorates HFD-induced hyperlipidemia via mTOR/P70S6K/SREBPs pathway

The mammalian target of rapamycin (mTOR)-sterol regulatory element-binding proteins (SREBPs) signaling promotes lipogenesis. However, mTOR inhibitors also displayed a significant side effect of hyperlipidemia. Thus, it is essential to develop mTOR-specific inhibitors to inhibit lipogenesis. Here, we...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ping-Ting Xiao, Zhi-Shen Xie, Yu-Jia Kuang, Shi-Yu Liu, Chun Zeng, Ping Li, E-Hu Liu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2021-11-01
Edice:	Acta Pharmaceutica Sinica B
Témata:	FKBP38 Hyperlipidemia 3,5,6,7,8,3ʹ,4ʹ-heptamethoxyflavone mTOR SREBP
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2211383521001039
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!